Solid Biosciences director granted 77,500 stock options
Solid Biosciences Inc. reported a Form 4 insider transaction showing a director stock option grant linked to board service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Solid Biosciences Inc. reported a Form 4 insider transaction showing a director stock option grant linked to board service. Options to purchase 77,500 shares of common stock at an exercise price of $6.61 per share were awarded to Board member Adam Stone as compensation.
The option vests in full on the earlier of the one-year anniversary of the June 10, 2026 grant date or immediately before the next annual stockholder meeting, with full acceleration upon specified change in control events. Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund Ltd. report an indirect pecuniary interest through a management fee offset and each disclaims beneficial ownership beyond that indirect interest.
Insider Trade Summary
Grant/Award: 77,500 shares
Grant/Award
1 txn
Insider
PERCEPTIVE ADVISORS LLC, EDELMAN JOSEPH, PERCEPTIVE LIFE SCIENCES MASTER FUND LTD
Role
Director, 10% Owner | Director, 10% Owner | Director, 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) | 77,500 | $0.00 | $0.00 |
Holdings After Transaction:
Director Stock Option (Right to Buy) — 77,500 contracts (Indirect, See footnote)
Footnotes (3)
- F1. This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
- F2. Consists of options to purchase shares of the Issuer's common stock awarded to Adam Stone in connection with his role as a member of the Issuer's Board of Directors. Mr. Stone is the Chief Investment Officer of Perceptive Advisors, LLC (the "Advisor"). The Advisor may be deemed to have an indirect pecuniary interest in the options to purchase common stock of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Stone's board service through a partial management fee offset.
- F3. Joseph Edelman is the managing member of the Advisor. The Advisor serves as the investment manager to Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Each of Mr. Edelman, the Advisor and the Master Fund disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, the Advisor or the Master Fund is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Key Figures
Option grant size: 77,500 shares
Exercise price: $6.61 per share
Expiration date: June 10, 2036
+3 more
6 metrics
Option grant size
77,500 shares
Director stock options underlying common stock
Exercise price
$6.61 per share
Strike price for director stock options
Expiration date
June 10, 2036
Option term for director grant
Shares after transaction
77,500 derivative units
Total options following grant for this entry
Transaction code
A (Grant, award, or other acquisition)
Indicates compensation-related option grant
Vesting schedule
1-year or next annual meeting
Earlier of one-year anniversary or next stockholder meeting
Key Terms
Director Stock Option (Right to Buy), pecuniary interest, change in control events, Section 16 of the Securities Exchange Act of 1934, +1 more
5 terms
Director Stock Option (Right to Buy) financial
"security_title: Director Stock Option (Right to Buy)"
pecuniary interest financial
"may be deemed to have an indirect pecuniary interest in the options"
change in control events financial
"will vest automatically as to 100% of the unvested portion upon specified change in control events"
Section 16 of the Securities Exchange Act of 1934 regulatory
"disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership"
A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.
beneficial ownership financial
"disclaims ... beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Solid Biosciences (SLDB) report on this Form 4?
Solid Biosciences reported a director stock option grant for Adam Stone covering 77,500 shares of common stock. The options were awarded as board compensation and reported by Perceptive Advisors LLC and related reporting persons with an indirect pecuniary interest.
What are the key terms of the 77,500 Solid Biosciences (SLDB) options?
The grant covers options to buy 77,500 Solid Biosciences common shares at an exercise price of $6.61 per share. The options expire on June 10, 2036, giving long-dated potential exposure to the company’s equity for the director’s board service.
How do the Solid Biosciences (SLDB) director options vest?
The options vest in full on the earlier of the one-year anniversary of the June 10, 2026 grant date or immediately before the next annual stockholder meeting. They also fully vest upon specified change in control events, providing accelerated vesting if such events occur.
Who benefits economically from the Solid Biosciences (SLDB) option grant?
The options were awarded to Adam Stone for board service, while Perceptive Advisors LLC may have an indirect pecuniary interest via a management fee offset. Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund Ltd. each disclaim beneficial ownership beyond that indirect interest.
Is this Solid Biosciences (SLDB) Form 4 a market purchase or sale?
No, the Form 4 reflects a grant/award acquisition of stock options, not an open-market trade. The transaction code is A, indicating a compensation-related grant rather than a buy or sell order executed in the public market.
What role does Perceptive Advisors play in this Solid Biosciences (SLDB) filing?
Perceptive Advisors LLC is a reporting person and may be deemed to have an indirect pecuniary interest because it can receive director compensation for Adam Stone’s service through a partial management fee offset, while still disclaiming beneficial ownership except for that indirect interest.
AI-generated analysis. How Rhea-AI works. Not financial advice.
